Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies-Reference-Cited by-同舟云学术

Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies

Published:2021-08-09 Issue:5 Volume:15 Page:1278-1287
ISSN:1936-0533
Container-title:Hepatology International
language:en
Short-container-title:Hepatol Int

Author:

Ito Takanori^ORCID,Ishigami Masatoshi,Yamamoto Takafumi,Mizuno Kazuyuki,Yamamoto Kenta,Imai Norihiro,Ishizu Yoji,Honda Takashi,Kawashima Hiroki,Yasuda Satoshi,Toyoda Hidenori,Yokota Kenji,Hase Tetsunari,Nishio Naoki,Maeda Osamu,Kato Masashi,Hashimoto Naozumi,Hibi Hideharu,Kodera Yasuhiro,Sone Michihiko,Ando Yuichi,Akiyama Masashi,Shimoyama Yoshie,Fujishiro Mitsuhiro

Publisher

Springer Science and Business Media LLC

Subject

Hepatology

Link

https://link.springer.com/content/pdf/10.1007/s12072-021-10238-y.pdf

Reference34 articles.

1. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.

2. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10.

3. Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13(8):473–86.

4. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–68.

5. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714–68.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucocorticoid efficacy and treatment strategies for drug-induced liver injury: a literature review;Molecular Biology Reports;2024-07-31

2. Clinical characteristics and prognosis of liver injury induced by immune checkpoint inhibitors in patients with malignancies: A real‐world retrospective study;British Journal of Clinical Pharmacology;2024-07-23

3. Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice;Oncology Letters;2024-06-25

4. Diagnostic guide for immune checkpoint inhibitor‐induced liver injury;Hepatology Research;2024-06-17

5. Guide for the Diagnosis of Immune Checkpoint Inhibitor-Induced Liver Injury;Kanzo;2024-06-01